SmartZyme's New Recombinant Factor VII – SZ7
SmartZyme is developing a mutated rFVIIa (“SZ7”) with
improved properties for severe bleeding indications.
We aim to provide a potent and safe coagulation agent that
is highly controlled and flexible in dosing, to control bleeding in surgical
Bleeding is a major complication of surgery and is
regarded as the No.1 cause of mortality in operating rooms worldwide.
While protocols for handling such bleeding events vary between
different health centers, a common theme exists in which a bleeding event is
first treated by ligation of the damaged vasculature/endothelium followed by
administration of blood units, plasma and platelets.
At this point, several other drugs are considered, with or
without coagulation agents, and if bleeding is persistent, a recombinant FVIIa designed for a different indication is
used in an off-label manner. This use is typically a last resort.
This common pathway to achieve hemostasis is prone for
failure since coagulation agents are introduced late in the process of
bleeding, after all other means have failed and significant coagulopathy has
SZ7 – SmartZyme’s Factor VII – is being engineered specifically to address the challenges associated with severe bleeding treatment:
- Fast clearance and improved localization – dramatically increase safety by reducing the risk of thrombosis
- Early administration as a first line treatment – reduce the use of blood product by orders of magnitude
- Low minimal effective dosage – ensure cost-effectiveness
- Flexible dosing – use as bolus or drip, including control of the drip rate